Bevacizumab biosimilar (Gedeon Richter)

贝伐珠单抗生物类似药 (Gedeon Richter)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBevacizumab biosimilar (Gedeon Richter)

Drug Alias Name贝伐赛珠单抗生物仿制药 (Gedeon Richter)贝伐珠单抗生物仿制药 (Gedeon Richter)贝伐单抗生物仿制药 (Gedeon Richter)贝伐人源化单抗生物仿制药 (Gedeon Richter)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGedeon Richter Plc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeL01XC07